Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
AβPP Processing—Limping Along on Lipases
3 February 2006. The search is on for factors that interact with the complex protein cutter at the upstream end of the amyloid cascade, that is, γ-secretase, and the enzyme phospholipase D1 (PLD1) could be one of them, according to back-to-back papers released in PNAS online this week. Paul Greengard at Rockefeller University, New York, and colleagues report that the lipase, which hydrolyzes phosphatidylcholine to generate phosphatidic acid, independently affects two processes, the trafficking of amyloid-β precursor protein (AβPP)-loaded vesicles through the trans-Golgi network, and the presenilin-catalyzed cleavage of amyloid-β (Aβ) from AβPP. The findings suggest that the phospholipase could be a target for therapeutics.

Though the work was a collaboration among many labs in the U.S., Rockefeller’s Dongming Cai was lead author on both papers. In the first, Cai and colleagues report how the phospholipase restores AβPP trafficking in neurons harboring presenilin (PS) mutants that cause familial AD. They found that when PLD1 is overexpressed in neuroblastoma cells, it rescues vesicle budding that has been impaired by the expression of PS1ΔE9, a presenilin mutant that causes overproduction of Aβ42 (see related ARF mutation data pages). The rescue seems to depend on the enzymatic activity of the lipase because overexpression of PLD1 increased budding of AβPP vesicles from the tans-Golgi network by over twofold, whereas overexpression of catalytically inactive lipase did not. The authors also found that the PLD1 inhibitor 1-butanol prevents increases in AβPP vesicle budding that occur in PS1 knockout fibroblasts. This not only supports the idea that the catalytic activity of PLD1 is crucial for its effects on budding, it also suggests that this action of PLD1 is independent of presenilin.

Yet there is another side to the story. In the second paper, the researchers report that PLD1 does interact with presenilin, after all: It apparently inhibits the protease, reducing production of Aβ. This action, by contrast, does not depend on the catalytic activity of PLD1. The conclusions are based on the following data. First, Cai used coimmunoprecipitation experiments to show that PLD1 and PS1 interact in embryonic stem cells. The authors narrowed down the site of interaction to the C-terminal end of PS because antibodies to a loop in this region blocked the interactions. Next, the authors determined that overexpression of PLD1 reduces intracellular and secreted Aβ by nearly half. However, unlike in the trafficking experiments, catalytically inactive PLD1 was just as effective here, reducing production of Aβ by similar amounts. The inactive lipase also bound to the C-terminal of PS1.

Taken together, the two papers show that PLD1 has mechanistically distinct actions on vesicle budding and PS1 activity. How the lipase affects the former is unclear, though given the dependence on catalytic activity, it may well be related to levels of phosphatidylcholine or phosphatidic acid. And, while PLD1 can accelerate vesicle budding in PS-negative cells, the lipase’s impact on vesicle trafficking may depend to some degree on the protease, because Cai also found that PLD1 activity was significantly reduced in cells expressing certain PS FAD mutations.

As for the effect of PLD1 on AβPP processing, this seems to be due to binding of the lipase to presenilin, causing disruption of the γ-secretase complex. The authors found that overexpression of PLD1 caused dissociation of the γ-secretase components—PEN2, APH1, and nicastrin—from PS1.

What effect PLD1 might have in vivo, and in particular on the pathology of AD, if any, is uncertain because most of the reported experiments depended on overexpression of PLD1 in cultured cells. When the authors used RNAi to knock down PLD1 protein by around 70 percent, they observed almost a threefold jump in intracellular Aβ, suggesting that relatively modest losses of PLD1 activity could have a significant effect on AβPP processing. In addition, they found that transfecting PLD1 into cortical neurons expressing the M146V PS1 mutation restored neurite outgrowth. When one considers that there may be a vicious cycle brought on by FAD PS mutations—first inactivating PLD1, which then fails to inhibit γ-secretase, which then produces more Aβ—then maintaining PLD1 activity might go some way toward ameliorating AD pathology.—Tom Fagan.

References:
Cai D, Zhong M, Wang R, Netzer WJ, Shields D, Zheng H, Sisodia SS, Foster DA, Gorelick FS, Xu H, Greengard P. Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer’s disease-linked presenilin-1 mutant neurons. PNAS. February 7, 2006;103:1936-1940. Abstract

Cai D, Netzer WJ, Zhong M, Lin Y, Du G, Frohman M, Foster DA, Sisodia SS, Xu H, Gorelick FS, Greengard P. Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation. PNAS. February 7, 2006;103:1941-1946. Abstract

 
Comments on News and Primary Papers
  Comment by:  Tobias Hartmann
Submitted 6 February 2006  |  Permalink Posted 6 February 2006

Aβ generation strongly depends on lipids. First of all, APP is a membrane protein, defining its most proximate neighboring molecules; second, substrate turnover of the secretases is regulated by membrane lipid composition; and third, Aβ peptides are signaling molecules involved in cholesterol and sphingolipid homeostasis. Now the Greengard lab adds a new stone to this mosaic. PLD1, a phospholipase, apparently binds to PS1 and absence of PLD1 increases Aβ generation. The story is complex because at least two independent pathways are involved. The first pathway modifies assembly or stability of γ-secretase and is independent of PLD1 enzymatic activity; the other one strictly depends the phospholipase activity, altering APP trafficking in the presence of PS1 and overexpressed PLD1. Moreover, it changes neurite growth, but only in the presence of PS-FAD.

Interestingly, PLD1 affects Aβ generation as much as it affects Notch cleavage. Gopal Thinakaran recently reported that NICD generation in adult cells, unlike Aβ, is produced outside of rafts. Does this indicate a role of PLD1...  Read more


  Primary Papers: Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons.

Comment by:  Tommaso Russo, ARF Advisor
Submitted 6 February 2006  |  Permalink Posted 6 February 2006
  I recommend this paper

  Primary Papers: Presenilin-1 uses phospholipase D1 as a negative regulator of beta-amyloid formation.

Comment by:  Tommaso Russo, ARF Advisor
Submitted 6 February 2006  |  Permalink Posted 6 February 2006
  I recommend this paper

  Comment by:  Frédéric Checler
Submitted 10 February 2006  |  Permalink Posted 10 February 2006

Several lines of evidence suggest that presenilins (PS) could contribute to both AβPP processing and trafficking to the membrane, but whether these two functions were related and intimately linked to the proposed catalytic activity of presenilins remained a matter of question. In these two back-to-back papers, the groups of Dr. Paul Greengard and Dr. Huaxi Xu interestingly suggest that phospholipase D1 (PLD1) could interact physically with PS, promote AβPP trafficking, and modulate Aβ production by apparently distinct mechanisms.

First, the group convincingly demonstrates that endogenous PS1 physically interacts with PLD1 but not with other PLD members, and binds to this phospholipase via its cytoplasmic loop domain. Apparently, PS1 recruits PLD1 in the Golgi/TGN, since PLD1 distributes within both cytosolic and Golgi/TGN compartments in wild-type ES cells, while PS1 deficiency triggers diffuse and only cytosolic localization of PLD1. Interestingly, PLD1 overexpression reduced the levels of both secreted and intracellular Aβ and increased βCTF, while PLD1 reduction by...  Read more

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad